Quercetin in thalassemia

Phase 2

Conditions: beta thalassemia major.
Cooley anaemia Severe beta thalassaemia Thalassaemia: intermedia major

Registration Number: IRCT201701172709N43

Lead Sponsor: Vice chancellor for research, Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 84

Inclusion Criteria

18 to 30 year old male and female beta thalassemia major patients; Inclination to cooperate and signing the written informed consent; A minimum of 2 years of blood transfusion history; blood specimen collection 20 days after the last blood transfusion; Regular and peculiar iron-chelating therapy with desferrioxamine; Vitamin C supplement intake with desferrioxamine; Serum ferritin level between 2500 to 3500 ng/ml
Exclusion criteria:
Uncontrollable and life threatening complication due to due to the supplement intake; A change in type or amount of the iron chelator; Pregnancy or lactation; Splenectomy; Hepatitis infection and other metabolic or infectious diseases; Less than 80% compliance of supplement intake; Consumption of drugs that interfere with quercetin; Drinking more than 500 mg/day of beverages rich in flavonoids; Smoking or alcohol consumption

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Malone dialdehyde (MDA). Timepoint: before and after the intervention. Method of measurement: nmol/gHb, colorimetry.;Total antioxidant capacity (TAC). Timepoint: before and after the intervention. Method of measurement: mmol/L, colorimetry.;Superoxide dismutase (SOD). Timepoint: before and after the intervention. Method of measurement: U/gHb, colorimetry.;Glutathione peroxidase (GPx). Timepoint: before and after the intervention. Method of measurement: U/gHb, colorimetry.

Secondary Outcome Measures